Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)
7.57
+0.02 (0.26%)
Feb 4, 2026, 3:04 PM CST
SHE:002581 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 325.3 | 506.4 | 151.91 | 183.8 | 187.8 | 284.15 |
Cash & Short-Term Investments | 325.3 | 506.4 | 151.91 | 183.8 | 187.8 | 284.15 |
Cash Growth | -24.14% | 233.35% | -17.35% | -2.13% | -33.91% | -74.65% |
Accounts Receivable | 199.47 | 93.32 | 172.62 | 179.72 | 272.96 | 353.77 |
Other Receivables | 113.42 | 52.24 | 78.87 | 18.36 | 13.49 | 16.75 |
Receivables | 312.89 | 145.55 | 251.49 | 198.09 | 286.45 | 370.52 |
Inventory | 127.32 | 79.64 | 85.31 | 80.04 | 64.33 | 70.87 |
Other Current Assets | 19.35 | 15.41 | 7.99 | 56.43 | 29.88 | 40.62 |
Total Current Assets | 784.85 | 747.01 | 496.71 | 518.36 | 568.45 | 766.16 |
Property, Plant & Equipment | 325.51 | 274.74 | 357.84 | 705.47 | 713.76 | 684.72 |
Long-Term Investments | 936.41 | 1,056 | 1,355 | 1,503 | 1,223 | 751.21 |
Other Intangible Assets | 97.8 | 93.47 | 108.29 | 126.32 | 134.29 | 144.55 |
Long-Term Deferred Tax Assets | 21.37 | 11.21 | 6.12 | 11.84 | 25.28 | 25.14 |
Long-Term Deferred Charges | 0.21 | 0.32 | 1.41 | 5.2 | 7.78 | 7.72 |
Other Long-Term Assets | 48.47 | 13.44 | 12.26 | 0.49 | 83.36 | 65.46 |
Total Assets | 2,215 | 2,196 | 2,337 | 2,870 | 2,756 | 2,445 |
Accounts Payable | 83.58 | 35.35 | 73.69 | 43.64 | 42.13 | 14.46 |
Accrued Expenses | 7.96 | 20.83 | 22.5 | 19.32 | 31.01 | 32.34 |
Short-Term Debt | 37.53 | 2.77 | 13.84 | 150.42 | 151.54 | 118.5 |
Current Portion of Leases | 21.73 | 0.17 | - | 13.46 | 15.83 | 20.82 |
Current Income Taxes Payable | 2.56 | - | 0.95 | 1.2 | 0.44 | 0.65 |
Current Unearned Revenue | 1.05 | 10.46 | 3.59 | 26.86 | 3.43 | 1.21 |
Other Current Liabilities | 32.53 | 13.03 | 19.03 | 109.38 | 14.17 | 18.9 |
Total Current Liabilities | 186.94 | 82.61 | 133.61 | 364.28 | 258.54 | 206.87 |
Long-Term Debt | 8.51 | - | - | - | - | - |
Long-Term Leases | 3.07 | - | 0.71 | 1.47 | 9.8 | 27.77 |
Long-Term Unearned Revenue | 5.49 | 5.49 | 5.49 | 6.71 | 9.74 | 10.96 |
Long-Term Deferred Tax Liabilities | 9.78 | 9.39 | 7.51 | 7.68 | 8.68 | 8.74 |
Other Long-Term Liabilities | 7.72 | 76.12 | 16.09 | 9.67 | - | - |
Total Liabilities | 221.51 | 173.61 | 163.41 | 389.82 | 286.76 | 254.33 |
Common Stock | 229.15 | 229.15 | 229.15 | 229.15 | 229.15 | 229.15 |
Additional Paid-In Capital | 880.95 | 866.41 | 873.93 | 858.5 | 858.29 | 858.29 |
Retained Earnings | 759.27 | 828.08 | 965.39 | 1,298 | 1,301 | 1,030 |
Total Common Equity | 1,869 | 1,924 | 2,068 | 2,385 | 2,388 | 2,117 |
Minority Interest | 123.74 | 98.67 | 105.26 | 94.94 | 81.11 | 73.43 |
Shareholders' Equity | 1,993 | 2,022 | 2,174 | 2,480 | 2,469 | 2,191 |
Total Liabilities & Equity | 2,215 | 2,196 | 2,337 | 2,870 | 2,756 | 2,445 |
Total Debt | 70.84 | 2.94 | 14.55 | 165.35 | 177.16 | 167.09 |
Net Cash (Debt) | 254.46 | 503.47 | 137.36 | 18.45 | 10.64 | 117.06 |
Net Cash Growth | -40.63% | 266.52% | 644.38% | 73.50% | -90.91% | -43.55% |
Net Cash Per Share | 0.39 | 0.76 | 0.21 | 0.03 | 0.02 | 0.18 |
Filing Date Shares Outstanding | 659.56 | 659.74 | 659.74 | 659.74 | 659.74 | 659.74 |
Total Common Shares Outstanding | 659.56 | 659.74 | 659.74 | 659.74 | 659.74 | 659.74 |
Working Capital | 597.91 | 664.4 | 363.1 | 154.08 | 309.91 | 559.3 |
Book Value Per Share | 2.83 | 2.92 | 3.14 | 3.62 | 3.62 | 3.21 |
Tangible Book Value | 1,772 | 1,830 | 1,960 | 2,259 | 2,254 | 1,973 |
Tangible Book Value Per Share | 2.69 | 2.77 | 2.97 | 3.42 | 3.42 | 2.99 |
Buildings | - | 393.55 | 486.08 | 639.62 | 612.92 | 426.35 |
Machinery | - | 431.4 | 432.25 | 413.16 | 424.47 | 345.34 |
Construction In Progress | - | 38.11 | 22.17 | 91.43 | 64.86 | 353.63 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.